What are the main reasons Amgen is reporting non-GAAP financial measures in this filing?

Amgen is reporting non-GAAP financial measures to provide investors with supplementary information that they believe facilitates additional analysis. These measures exclude certain expenses that the company deems are not indicative of its ongoing operational performance, such as acquisition-related expenses, cost-saving initiative expenses, and stock-based compensation. They also aim to provide a more comparable view of profitability, particularly by treating acquired intellectual property similarly to internally developed assets.

What were the primary components of the acquisition-related expenses mentioned?

The acquisition-related expenses detailed in this filing primarily relate to the Onyx Pharmaceuticals acquisition. These include non-cash amortization of intangible assets acquired, accelerated equity compensation for Onyx employees, and transaction costs. Similar expenses related to prior business combinations were also adjusted for in the reporting periods.

How is Free Cash Flow (FCF) calculated by Amgen, and why is it important?

Amgen defines Free Cash Flow (FCF) as cash flow from operations (determined in accordance with GAAP) minus capital expenditures. The company believes FCF is an important measure of liquidity that provides investors with an additional metric to analyze the company's ability to generate cash after accounting for investments in its business.

Where can I find the detailed financial results and the reconciliation of non-GAAP to GAAP measures?

The detailed financial results for the three and twelve months ended December 31, 2013, along with the reconciliations of non-GAAP financial measures to their most comparable GAAP measures, are provided in the press release dated January 28, 2014, which is attached as Exhibit 99.1 to this 8-K filing.

AMGN 8-K: Earnings & Results

Summary

This 8-K filing from Amgen Inc. (AMGN) on January 28, 2014, primarily serves to announce the company's unaudited financial results for the fourth quarter and full year ended December 31, 2013. The report highlights Amgen's use of non-GAAP financial measures, which exclude various items such as stock-based compensation, acquisition-related expenses (particularly from the Onyx Pharmaceuticals acquisition), cost-saving initiative expenses, legal expenses, and non-cash interest expense. These adjustments are presented to provide supplementary insights into the company's operational performance and financial condition. Investors should note the extensive detail provided on the adjustments made to GAAP figures to arrive at the non-GAAP metrics. The company believes these non-GAAP measures offer a more comparable view of profitability, especially by treating acquired intellectual property similarly to internally developed assets and by facilitating comparisons across different periods. The report also introduces Free Cash Flow (FCF) as a non-GAAP liquidity measure, calculated by subtracting capital expenditures from cash flow from operations.

Key Highlights

1Amgen reported its unaudited financial results for the three and twelve months ended December 31, 2013.
2The company utilized non-GAAP financial measures, excluding items like stock-based compensation, acquisition-related expenses, cost-savings initiatives, legal expenses, and non-cash interest.
3Significant acquisition-related expenses were detailed, particularly stemming from the Onyx Pharmaceuticals acquisition, including amortization of intangible assets and equity compensation.
4Amgen presented non-GAAP adjusted operating expenses, adjusted provision for income taxes, adjusted net income, and adjusted earnings per share.
5Free Cash Flow (FCF) was reported as a non-GAAP measure to provide an additional perspective on liquidity.
6The company explained its rationale for using non-GAAP measures, aiming to enhance comparability and provide supplementary analysis for investors.
7The filing includes reconciliations of non-GAAP financial measures to their most comparable GAAP measures as part of the attached press release (Exhibit 99.1).

AMGEN INC 8-K Report, Financial Results (Jan 28, 2014)

Summary

Key Highlights

Frequently Asked Questions